At the 2022 Fall Clinical Dermatology Conference in Las Vegas, Aaron S. Farberg, MD, shares data on the treatment of plaque psoriasis using tildrakizumab-asmn.
Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.
Deucravacitinib offers new hope for those with moderate-to-severe plaque psoriasis.
The company announced the results from its long-term extension study, highlighting improved efficacy outcomes, quality of life, and tolerability data.
The New England Journal of Medicine has published the clinical trial data from the PSOARING 1 and PSOARING 2 studies on tapinarof treatment for plaque psoriasis.
In a video for Dermatology Times®, Mark Lebwohl, MD, details how to match patients with the right psoriasis treatment for their specific needs.
The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.
Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.
A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.
A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.